20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.06 · Revenue $891000.00 · 1 analysts
Est. EPS $-0.07 · Revenue $1.07M · 1 analysts
Est. EPS $-0.42 · Revenue $2.95M · 1 analysts
Est. EPS $-0.38 · Revenue $5.77M · 1 analysts
EPS $-0.17 · Revenue $417979.00
EPS $-1.16 · Revenue $1.75M
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $2.0M | +16.7% | +106.7% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-3.7M | +32.7% | +30.7% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +29.6% | +43.8% | +134.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -162.9% | +49.6% | +58.3% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -182.8% | +42.3% | +66.5% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-1.9B | -73770.0% | +53.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -93867.7% | -63194.5% | +77.5% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -6678949.3% | -6770923.6% | -46.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.60x | -60.2% | +9.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $4.1M | +14.5% | +5.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.60 vs -0.42 | -42.9% | -0.26 vs -0.12 | -116.7% |
| Revenue Surprise | $2.0M vs $2.9M | -30.6% | $730571 vs $636000 | +14.9% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Apr 2, 2026 | Bergman Alan B. | officer: Chief Financial Officer | Stock Option | A | 100,000 | $1.88 |
| Apr 2, 2026 | Zhou Jiming | officer: Chief Operating Officer | Stock Option | A | 150,000 | $1.88 |
| Mar 3, 2026 | Cohen Jonathan M | director, 10 percent owner, officer: Chief Executive Officer | Stock Option | A | 352,936 | $3.39 |
| Feb 19, 2026 | Rollins John Woodson | director | Common Stock | A | 6,135 | — |
| Feb 19, 2026 | Rollins John Woodson | director | Common Stock | A | 13,029 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Jonathan Cohen | Founder, CEO, President & Director | USD 325,499 | Male | 1964 | Active |
Jiming Zhou | Chief Operating Officer | USD 225,647 | — | 1968 | Active |
Michael S. Lebowitz | Chief Scientific Officer | USD 89,600 | — | 1969 | Active |
Alan Bergman | Chief Financial Officer | — | Male | 1969 | Active |
Ronald R. Baker | Chief Business Officer | — | Male | 1951 | Active |
David Lees | Director of Sales | — | Male | — | Active |
Marc Gordon | Controller | — | — | — | Active |
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
CEO Jonathan Cohen to Detail the Company's Strongest Quarterly Performance Since Commercial Launch of Multi-Cancer Early Detection Testing, Key Takeaways from the Next Generation Dx Summit, and Path to Broader Commercial Adoption Webinar to Be Held Wednesday, September 2, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md.
Best Quarter of Flagship Multi-Cancer Early Detection Testing; OneTest™ Revenue Increased 47% Year-Over-Year to $0.7 Million; Gross Profit Increased 87% to $0.3 Million, with Gross Margin Expanding to 41.7% from 30.5% Company Expands OneTest™ Across Firefighter, Occupational Health, Military, and Physician Practice Markets Cash Position Strengthened to $4.5 Million as of June 30, 2026, with All Convertible Note Debt Eliminated During the Quarter GAITHERSBURG, Md., Aug. 17, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported its financial and operational results for the second quarter ended June 30, 2026.
Chief Executive Officer Jonathan Cohen to Discuss BIO Asia-Taiwan Participation and Strategic Meetings in Taipei, Tokyo, and Seoul Webinar to Be Held Wednesday, August 5, 2026 at 12:00 p.m. Eastern Time; Registration Is Now Open GAITHERSBURG, Md.
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
| Report Date | Employees | Form Type | Filing Date | SEC Filing |
|---|---|---|---|---|
| Dec 31, 2025 | 4 | 10-K | Mar 31, 2026 | View |
